0000000000241113

AUTHOR

Chryssoula Tzialla

0000-0002-6040-2381

showing 4 related works from this author

Optimised versus standard dosing of vancomycin in infants with Gram-positive sepsis (NeoVanc): a multicentre, randomised, open-label, phase 2b, non-i…

2022

Summary Background Vancomycin is the most widely used antibiotic for neonatal Gram-positive sepsis, but clinical outcome data of dosing strategies are scarce. The NeoVanc programme comprised extensive preclinical studies to inform a randomised controlled trial to assess optimised vancomycin dosing. We compared the efficacy of an optimised regimen to a standard regimen in infants with late onset sepsis that was known or suspected to be caused by Gram-positive microorganisms. Methods NeoVanc was an open-label, multicentre, phase 2b, parallel-group, randomised, non-inferiority trial comparing the efficacy and toxicity of an optimised regimen of vancomycin to a standard regimen in infants aged …

medicine.medical_specialtyTime FactorsPopulationEquivalence Trials as TopicLoading doseArticlelaw.inventionGram-positiveRandomized controlled triallawVancomycinIntensive careInternal medicineIntensive Care Units NeonatalSepsisDevelopmental and Educational PsychologyClinical endpointMedicineHumansDosingeducationInfusions Intravenouseducation.field_of_studybusiness.industryInfant NewbornInfantdosingUnited KingdomAnti-Bacterial AgentsEuropeRegimenTreatment OutcomeSpainRelative riskPediatrics Perinatology and Child Healthsepsibusiness
researchProduct

Exposure to Gastric Acid Inhibitors Increases the Risk of Infection in Preterm Very Low Birth Weight Infants but Concomitant Administration of Lactof…

2018

Objective: To investigate whether exposure to inhibitors of gastric acidity, such as H2 blockers or proton pump inhibitors, can independently increase the risk of infections in very low birth weight (VLBW) preterm infants in the neonatal intensive care unit. Study design: This is a secondary analysis of prospectively collected data from a multicenter, randomized controlled trial of bovine lactoferrin (BLF) supplementation (with or without the probiotic Lactobacillus rhamnosus GG) vs placebo in prevention of late-onset sepsis (LOS) and necrotizing enterocolitis (NEC) in preterm infants. Inhibitors of gastric acidity were used at the recommended dosages/schedules based on the clinical judgmen…

ColonizationProton Pump InhibitorNeonatal intensive care unitAdministration OralHistamine H2 AntagonistProbioticGastroenterologyPediatricsH2 blocker0302 clinical medicineRisk FactorsInfant Very Low Birth Weight030212 general & internal medicineCandidaVLBW neonateLacticaseibacillus rhamnosusGestational agePerinatology and Child HealthHistamine H2 AntagonistsItalyNecrotizing enterocolitismedicine.symptomInfectionInfant PrematureHumanmedicine.medical_specialtyBirth weightGastric AcidSepsis03 medical and health sciencesEnterocolitis NecrotizingIntensive Care Units NeonatalSepsis030225 pediatricsInternal medicinemedicineH2 blockersHumansDietary Supplementbusiness.industryRisk FactorProbioticsInfant NewbornProton Pump Inhibitorsmedicine.diseaseLow birth weightLactoferrinConcomitantDietary SupplementsPediatrics Perinatology and Child HealthVLBW neonatesCandida; Colonization; H2 blockers; Infection; Lactoferrin; VLBW neonates; Pediatrics Perinatology and Child HealthGastric acidLactobacillus rhamnosubusinessNew Zealand
researchProduct

Invasive candida infections in neonates after major surgery: Current evidence and new directions

2021

Infections represent a serious health problem in neonates. Invasive Candida infections (ICIs) are still a leading cause of mortality and morbidity in neonatal intensive care units (NICUs). Infants hospitalized in NICUs are at high risk of ICIs, because of several risk factors: broad spectrum antibiotic treatments, central catheters and other invasive devices, fungal colonization, and impaired immune responses. In this review we summarize 19 published studies which provide the prevalence of previous surgery in neonates with invasive Candida infections. We also provide an overview of risk factors for ICIs after major surgery, fungal colonization, and innate defense mechanisms against fungi, a…

0301 basic medicineMicrobiology (medical)Antifungalmedicine.medical_specialtymedicine.drug_classInvasive Candida infections030106 microbiologylcsh:MedicineInvasive Candida infectionCandida infections03 medical and health sciencesBroad spectrumNeonatal surgeryinvasive <i>Candida</i> infections0302 clinical medicineInvasive fungal infectionInvasive fungal infectionsIntensive careEpidemiologyFungal colonizationImmunology and AllergyMedicineAntifungal prophylaxi030212 general & internal medicineMolecular BiologyNewbornsGeneral Immunology and Microbiologybusiness.industrylcsh:RImpaired immune responsesNewbornSurgeryNeonatal surgeryInfectious DiseasesSettore MED/20SurgeryAntifungal prophylaxisAntifungal prophylaxis; Invasive Candida infections; Invasive fungal infections; Neonatal surgery; Newborns; Surgerybusiness
researchProduct

Antimicrobial therapy in neonatal intensive care unit

2015

Severe infections represent the main cause of neonatal mortality accounting for more than one million neonatal deaths worldwide every year. Antibiotics are the most commonly prescribed medications in neonatal intensive care units (NICUs) and in industrialized countries about 1% of neonates are exposed to antibiotic therapy. Sepsis has often nonspecific signs and symptoms and empiric antimicrobial therapy is promptly initiated in high risk of sepsis or symptomatic infants. However continued use of empiric broad-spectrum antibiotic treatment in the setting of negative cultures especially in preterm infants may not be harmless. The benefits of antibiotic therapy when indicated are clearly enor…

medicine.medical_specialtyNeonatal intensive care unitmedicine.drug_classAntibioticsReviewGlobal HealthInfant Newborn DiseasesSepsisIntensive Care Units NeonatalIntensive caremedicineHumansAntibiotic prophylaxisAdverse effectIntensive care medicineEmpiric therapyAntibiotic stewardshipNeonatal sepsisbusiness.industryInfant NewbornAntibioticAntibiotic ProphylaxisNewbornmedicine.diseaseAnti-Bacterial AgentsAntibiotic; Antibiotic stewardship; Empiric therapy; Neonatal sepsis; Newborn; Resistant bacteria; Pediatrics Perinatology and Child HealthPediatrics Perinatology and Child HealthNeonatal sepsisNeonatal sepsiResistant bacteriabusinessEmpiric therapyItalian Journal of Pediatrics
researchProduct